Organon & Co. (OGN) Competitors

Organon & Co. (NYSE:OGN) and Blueprint Medicines (NASDAQ:BPMC) are both mid-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, valuation, dividends, analyst recommendations, profitability, media sentiment, institutional ownership and earnings.

Do analysts rate OGN or BPMC?

Organon & Co. currently has a consensus price target of $18.00, indicating a potential upside of 87.99%. Blueprint Medicines has a consensus price target of $128.25, indicating a potential downside of 0.85%. Given Organon & Co.'s stronger consensus rating and higher possible upside, research analysts clearly believe Organon & Co. is more favorable than Blueprint Medicines.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Organon & Co.	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.50
Blueprint Medicines	0 Sell rating(s)	17 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.24

Do institutionals and insiders believe in OGN or BPMC?

77.4% of Organon & Co. shares are owned by institutional investors. 1.4% of Organon & Co. shares are owned by insiders. Comparatively, 4.2% of Blueprint Medicines shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Which has better valuation and earnings, OGN or BPMC?

Organon & Co. has higher revenue and earnings than Blueprint Medicines. Blueprint Medicines is trading at a lower price-to-earnings ratio than Organon & Co., indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Organon & Co.	$6.40B	0.39	$864M	$2.88	3.32
Blueprint Medicines	$562.12M	14.86	-$67.09M	-$2.47	-52.37

Does the media favor OGN or BPMC?

In the previous week, Organon & Co. had 47 more articles in the media than Blueprint Medicines. MarketBeat recorded 55 mentions for Organon & Co. and 8 mentions for Blueprint Medicines. Blueprint Medicines' average media sentiment score of 1.33 beat Organon & Co.'s score of 0.15 indicating that Blueprint Medicines is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Organon & Co.	7 Very Positive mention(s)	3 Positive mention(s)	34 Neutral mention(s)	8 Negative mention(s)	3 Very Negative mention(s)	Neutral
Blueprint Medicines	7 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Which has more risk and volatility, OGN or BPMC?

Organon & Co. has a beta of 0.6, meaning that its share price is 40% less volatile than the S&P 500. Comparatively, Blueprint Medicines has a beta of 0.89, meaning that its share price is 11% less volatile than the S&P 500.

Is OGN or BPMC more profitable?

Organon & Co. has a net margin of 11.92% compared to Blueprint Medicines' net margin of -27.70%. Organon & Co.'s return on equity of 227.43% beat Blueprint Medicines' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Organon & Co.	11.92%	227.43%	7.34%
Blueprint Medicines	-27.70%	-64.60%	-17.22%

Summary

Organon & Co. beats Blueprint Medicines on 11 of the 16 factors compared between the two stocks.